<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773030</url>
  </required_header>
  <id_info>
    <org_study_id>CC-220-MM-001</org_study_id>
    <secondary_id>U1111-1182-9200</secondary_id>
    <secondary_id>2016-000860-40</secondary_id>
    <nct_id>NCT02773030</nct_id>
  </id_info>
  <brief_title>A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma</brief_title>
  <official_title>A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study
      consisting of two parts: dose escalation (Part 1) for CC-220 MonoT, CC-220 in combination
      with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and
      CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220
      MonoT, CC-220 in combination with DEX (DoubleT) for Relapsed Refractory Multiple Myeloma and
      CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the
      option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The
      dose of CC-220 will not be higher than the dose of CC-220 used in combination with
      dexamethasone in Cohort B that has been determined to be safe. Progressive disease must be
      confirmed in accordance with international myeloma working group (IMWG) criteria.

      The starting dose of DEX will be 40 mg for subjects who are ≤75 years of age and 20 mg for
      subjects who are &gt;75 years of age, given once weekly. This treatment will continue until PD,
      unacceptable toxicity or the subject withdraws consent.

      For Cohorts A and B, the starting dose level of CC-220, dose level 1, is 0.3 mg. A dose level
      -1, of 0.15 mg, may also be evaluated if the starting dose level of 0.3 mg for 21 days of a
      28-day cycle is not tolerated. For Cohorts E and F, the starting dose level of CC-220, dose
      level 1, is one dose level below the maximum dose for Cohort B that has been determined to be
      safe by the dose escalation committee (DEC) at the start of enrollment for both cohorts. For
      Cohort E in addition to CC-220 and DEX, daratumumab will be administered intravenously (IV)
      at a 16mg/kg dose. For Cohort F in addition to CC-220 and DEX, bortezomib will be
      administered subcutaneous (SC) at a 1.3mg/m2 dose.

      All subjects with a minimal response (MR) or better who discontinue study treatment in Part 1
      or Part 2 of the study for a reason other than PD or withdrawal of consent from the study
      will be followed for response assessment every 28 days (every 21 days for Cohort F) until PD.

      The study will be conducted in compliance with the International Council for Harmonisation
      (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good
      Clinical Practice (GCP) and applicable regulatory requirements.

      The initiation of Part 2 will begin when the RP2D is established in Part 1 in either Cohort A
      or Cohort B. Either cohort may begin once the RP2D is determined for each cohort
      independently during Part 1. All expansion decisions will be determined by the DEC after
      review of all safety, PK, biomarker and preliminary efficacy data, as applicable. During Part
      2, the Independent Expert Reviewer will review safety data and any other data deemed relevant
      so that subject safety is ensured.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">May 9, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish maximum tolerated doses (MTDs) of CC-220 as monotherapy and in combination with other treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Establish the maximum tolerated doses (MTDs) of CC-220 monotherapy, in combination with DEX, and in combination with DEX and daratumumab (CC-220Dd), in combination with DEX and bortezomib (CC-220Vd), and in combination with DEX and carfilzomib (CC-220Kd)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish Recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy and in combination with other treatment</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>RP2D is defined as the dose selected for phase 2 based on safety, pharmacokinetics and biomarker data from phase 1 of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) of CC-220 in combination with DEX in Cohort D in Part 2</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Rajkumar, 2011) in CC-220 in combination with DEX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Type, frequency, seriousness and severity of adverse events (AEs) (and AEs of special interest) and relationship of AEs to investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Rajkumar, 2011) for subjects who achieved partial response (PR) or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Is defined as the time from the first date of dosing of IP to the first date of documented response (partial response [PR] or greater).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Is defined as Time from the first documentation of response (PR or greater) to the first documentation of Progressive disease (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐AUC 0-τ</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐Cmax</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Maximum plasma concentration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐Tmax</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Time to Maximum plasma concentration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐t1/2</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Terminal-phase elimination half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐CLss/F</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Apparent total plasma clearance when dosed daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐Vss/F</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Apparent total volume of distribution at steady state when dosed orally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Part 2 RRMM cohorts</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Time from first dose of IP to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very good partial response or better rate (VGPR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Rajkumar, 2011) for subjects who achieved VGPR or better</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">449</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort A: CC-220 Monotherapy - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: CC-220 in combination with Dexamethasone - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects &gt;75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: CC-220 Monotherapy - Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: CC-220 in combination with Dexamethasone - Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects &gt;75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects &gt;75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Intravenous DARA at dose 16 mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: CC-220 with DEX and bortezomib - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.
Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects &gt;75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.
Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G1-CC-220 in combination with CFZ and DEX -Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle
Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects &gt; 75 years old, the DEX dose will be 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle
Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects &gt;75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above).
Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (&gt; 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (&gt; 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.
Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle.
Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (&gt; 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.
Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.</description>
    <arm_group_label>Cohort A: CC-220 Monotherapy - Part 1</arm_group_label>
    <arm_group_label>Cohort B: CC-220 in combination with Dexamethasone - Part 1</arm_group_label>
    <arm_group_label>Cohort C: CC-220 Monotherapy - Part 2</arm_group_label>
    <arm_group_label>Cohort D: CC-220 in combination with Dexamethasone - Part 2</arm_group_label>
    <arm_group_label>Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1</arm_group_label>
    <arm_group_label>Cohort F: CC-220 with DEX and bortezomib - Part 1</arm_group_label>
    <arm_group_label>Cohort G1-CC-220 in combination with CFZ and DEX -Part 1</arm_group_label>
    <arm_group_label>Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1</arm_group_label>
    <arm_group_label>CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2</arm_group_label>
    <arm_group_label>CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <arm_group_label>CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <other_name>Iberdomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects &gt;75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
    <arm_group_label>Cohort B: CC-220 in combination with Dexamethasone - Part 1</arm_group_label>
    <arm_group_label>Cohort D: CC-220 in combination with Dexamethasone - Part 2</arm_group_label>
    <arm_group_label>Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1</arm_group_label>
    <arm_group_label>Cohort F: CC-220 with DEX and bortezomib - Part 1</arm_group_label>
    <arm_group_label>Cohort G1-CC-220 in combination with CFZ and DEX -Part 1</arm_group_label>
    <arm_group_label>Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1</arm_group_label>
    <arm_group_label>CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2</arm_group_label>
    <arm_group_label>CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <arm_group_label>CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.</description>
    <arm_group_label>Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib (BTZ)</intervention_name>
    <description>Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.</description>
    <arm_group_label>Cohort F: CC-220 with DEX and bortezomib - Part 1</arm_group_label>
    <arm_group_label>CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <arm_group_label>CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.</description>
    <arm_group_label>Cohort G1-CC-220 in combination with CFZ and DEX -Part 1</arm_group_label>
    <arm_group_label>Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. All subjects in RRMM cohorts must have a documented diagnosis of Multiple Myeloma and
        have measurable disease defined as:

          1. M-protein (serum and/or urine protein electrophoresis (sPEP or uPEP)): sPEP ≥0.5 g/dL
             or uPEP ≥200 mg/24 hours and/or

          2. Light chain Multiple Myeloma without measurable disease in the serum or urine: serum
             immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum
             immunoglobulin kappa lambda free light chain ratio 2. All subjects in RRMM cohorts
             must have documented disease progression on or within 60 days from the last dose of
             their last myeloma therapy. Subjects who had CAR T therapy as their last myeloma
             therapy must have documented disease progression.

             3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 3.
             Subject must have documented diagnosis with previously untreated symptomatic MM as
             defined by the criteria below (Rajkumar, 2016): MM diagnostic criteria;

             - Clonal bone marrow plasma cells ≥ 10% or biopsy-proven bony or extramedullary
             plasmacytoma

             - Any one or more of the following myeloma defining events:

               -  One or more of the following myeloma-related organ dysfunction (at least one of
                  the following);

                  • [C] Calcium elevation (serum calcium &gt; 0.25 mmol/L [&gt; 1 mg/dL] higher than the
                  upper limit of laboratory normal or &gt; 2.75 mmol/L [&gt; 11 mg/dL])

                  • [R] Renal insufficiency (serum creatinine &gt; 2 mg/dl [&gt; 177 μmol/L] or
                  creatinine clearance &lt; 40 ml/min)

                    -  [A] Anemia (hemoglobin &lt; 10 g/dl or &gt; 2 g/dL below the lower limit of
                       laboratory normal)

                    -  [B] Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal
                       radiography, computed tomography (CT), or positron emission tomography
                       (PET)/CT

               -  One or more of the following biomarkers of malignancy:

                    -  Clonal bone marrow plasma cell percentage* ≥ 60%

                    -  Abnormal serum free light-chain (FLC) ratio ≥ 100 (involved kappa) or &lt;0.01
                       (involved lambda) and involved FLC level must be ≥ 100 mg/L

                    -  &gt;1 focal lesion detected by magnetic resonance imaging (MRI) (at least 5 mm
                       in size)

             AND have measurable disease, as assessed by central laboratory, defined by any of the
             following:

             - Immunoglobulin (Ig)G myeloma: serum M-protein level ≥ 1.0 g/dL or urine M-protein
             level ≥ 200 mg/24 hours; or

             - IgA, IgM, IgD, or IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine
             M-protein level ≥ 200 mg/24 hours; or

             - Light chain multiple myeloma without measurable disease in serum or urine: serum FLC
             ≥ 100 mg/L and abnormal kappa lambda (κ/λ) ratio 4. Subjects in Cohort J1 are not
             considered by the investigator as eligible for high-dose chemotherapy and autologous
             stem cell transplantation due to:

             - Age ≥65 years, OR

             - In subjects &lt;65 years: presence of important comorbid condition(s) likely to have a
             negative impact on tolerability of high-dose chemotherapy with autologous stem cell
             transplantation.

             5. Subjects in Cohort J2 are considered by the investigator as eligible for high-dose
             chemotherapy and autologous stem cell transplantation according to the institution's
             criteria based on age, medical history, cardiac and pulmonary status, overall health
             and condition, co-morbid condition(s), physical examination, and laboratory data.

             Exclusion Criteria:

             1. Subject has nonsecretory or oligosecretory multiple myeloma 2. Subjects with Plasma
             Cell leukemia or amyloidosis 3. Any of the following laboratory abnormalities

             • Absolute neutrophil count (ANC) &lt;1,000/μL

             • Platelet count &lt; 75,000/μL for Part 1. For Part 2; platelet count &lt; 75,000/μL for
             subjects in whom &lt; 50% of bone marrow nucleated cells are plasma cells; otherwise
             platelet count &lt; 50,000/μL (transfusions are not permitted to achieve minimum platelet
             counts

             • Corrected serum calcium &gt;13.5 mg/dL (&gt;3.4 mmol/L)

               -  Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)
                  or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)≥2.0
                  x upper limit of normal (ULN)

               -  Serum total bilirubin and alkaline phosphatase &gt;1.5 x ULN

               -  Subjects with serious renal impairment creatinine clearance ([CrCl] &lt;45 mL/min)
                  or requiring dialysis would be excluded 4. Subjects with peripheral neuropathy
                  ≥Grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>April Sorrell-Taylor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert H Lurie Comprehensive Cancer Center NW Univ</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Med</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital Weil Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at the University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Claude Huriez</name>
      <address>
        <city>Lile Cedax</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU La Miletrie</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Kinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UKT Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaets-klinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Policlinico San Matteo - Universita di Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma - Centro di Ematologia</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osp. S.Giovanni Battista Le Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto-city</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastrich</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol Can Ruti</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Val d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia-Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Pesset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genesis Care</name>
      <address>
        <city>Oxford</city>
        <zip>OX4 6LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Institut of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>CC-220</keyword>
  <keyword>Relapsed and refractory multiple myeloma</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

